NCT00679731

A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis

A Phase 3, Multicenter, Randomized, Double-blind Study Comparing the Safety Efficacy of ABT-874 to Methotrexate in Subjects With Moderate to Severe Chronic Plaque Psoriasis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 317 (actual)
• Sponsor: AbbVie (prior sponsor, Abbott) · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is being conducted to compare the efficacy of ABT-874 versus Methotrexate in subjects with moderate to severe plaque psoriasis.

Detailed description

This study is only being conducted in the EU and Canada

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	ABT-874	200 mg at week 0 and 4 and 100mg at week 8 and every 4 weeks there after administered as aSQ injection
DRUG	Methotrexate	5.0 to 25 mg weekly

Timeline

• Start date: 2008-04-01
• Primary completion: 2009-11-01
• Completion: 2009-11-01
• First posted: 2008-05-19
• Last updated: 2013-01-29

Locations

43 sites across 14 countries: Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Spain, Sweden, Switzerland, United Kingdom